IL1B and type 2 diabetes mellitus: Anti‐inflammation shows the therapeutic potential of T2DM.[39, 40] Although most anti‐inflammatory agents in clinical trials have been proven negative, including anti‐IL‐1β or anti‐TNFα antibodies,[41] salicylate or other salicylic acid derivatives reduce blood glucose in clinical trials by inhibiting IKK/NF‐κB,[42] indicating therapeutic strategies able to modulate widely inflammatory agents show more potential than target a single cytokine.